Mettler-Toledo reported Q4 2025 results that exceeded expectations in some areas but fell short in others. The company posted sales of $1.13 billion, up 8.1% year-over-year, which topped revenue expectations. Non-GAAP earnings per share came in at $13.36, beating the consensus estimate of $12.76 by $0.60 and representing an increase from $12.41 in the prior year period. However, the company's Q1 2026 revenue guidance of $910.3 million came in 3.1% below analyst estimates. The stock declined following the earnings announcement as several analysts adjusted their price targets and ratings in response to the weak forward guidance that overshadowed the better-than-expected quarterly results.
Read full analysisMettler-Toledo reported Q4 2025 results that exceeded expectations in some areas but fell short in others. The company posted sales of $1.13 billion, up 8.1% year-over-year, which topped revenue expectations. Non-GAAP earnings per share came in at $13.36, beating the consensus estimate of $12.76 by $0.60 and representing an increase from $12.41 in the prior year period. However, the company's Q1 2026 revenue guidance of $910.3 million came in 3.1% below analyst estimates. The stock declined following the earnings announcement as several analysts adjusted their price targets and ratings in response to the weak forward guidance that overshadowed the better-than-expected quarterly results.
Mettler-Toledo International Inc. (MTD) is a publicly traded company in the Healthcare sector.